tiprankstipranks
Advertisement
Advertisement

KALV Stock Latest News

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
Company AnnouncementsChiesi Group Completes Acquisition of KalVista Pharmaceuticals
10d ago
8K
KALV
Chiesi Group completes KalVista acquisition
PremiumThe Fly
Chiesi Group completes KalVista acquisition
10d ago
KALV
KalVista’s Sebetralstat Extension Study Completion Sets Up Key Catalyst for KALV Investors
PremiumCompany Announcements
KalVista’s Sebetralstat Extension Study Completion Sets Up Key Catalyst for KALV Investors
16d ago
KALV
KalVista presents new data on injectable on-demand treatment in children
PremiumThe Fly
KalVista presents new data on injectable on-demand treatment in children
24d ago
KALV
Merger Agreement With Chiesi Puts Strategic Handcuffs on KalVista, Raising Execution and Liquidity Risks
PremiumCompany Announcements
Merger Agreement With Chiesi Puts Strategic Handcuffs on KalVista, Raising Execution and Liquidity Risks
1M ago
KALV
KalVista downgraded to Hold from Buy at Stifel
PremiumThe FlyKalVista downgraded to Hold from Buy at Stifel
1M ago
KALV
KalVista downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
KalVista downgraded to Neutral from Buy at H.C. Wainwright
2M ago
KALV
KalVista downgraded to Hold from Buy at Needham
Premium
The Fly
KalVista downgraded to Hold from Buy at Needham
2M ago
KALV
KalVista downgraded to Hold from Buy at JonesResearch
PremiumThe Fly
KalVista downgraded to Hold from Buy at JonesResearch
2M ago
KALV
KalVista Downgraded to $27 Target as Chiesi’s All-Cash Takeout Caps Near-Term Upside, Supporting Hold Rating
PremiumRatings
KalVista Downgraded to $27 Target as Chiesi’s All-Cash Takeout Caps Near-Term Upside, Supporting Hold Rating
2M ago
KALV
KalVista downgraded to Market Perform from Outperform at Leerink
PremiumThe Fly
KalVista downgraded to Market Perform from Outperform at Leerink
2M ago
KALV
KalVista downgraded to Market Perform from Outperform at Citizens
PremiumThe Fly
KalVista downgraded to Market Perform from Outperform at Citizens
2M ago
KALV
KalVista moved to No Rating at BofA
PremiumThe FlyKalVista moved to No Rating at BofA
2M ago
KALV
Midday Fly By: Seagate reports Q3 beat, Visa reports mixed Q2
Premium
The Fly
Midday Fly By: Seagate reports Q3 beat, Visa reports mixed Q2
2M ago
V
BE
Chiesi to Acquire KalVista Pharmaceuticals in Cash Merger
Premium
Company Announcements
Chiesi to Acquire KalVista Pharmaceuticals in Cash Merger
2M ago
8K
KALV
Chiesi Group to acquire KalVista for $27.00 per share in cash
PremiumThe Fly
Chiesi Group to acquire KalVista for $27.00 per share in cash
2M ago
KALV
3 ‘Strong Buy’ Stocks With Up to 180% Upside to Buy Now, According to Top Analysts, 4/16/2026
PremiumMarket News
3 ‘Strong Buy’ Stocks With Up to 180% Upside to Buy Now, According to Top Analysts, 4/16/2026
2M ago
ACRS
KALV
Ekterly: Strong Global Launch Momentum and Pediatric Upside Support Multi‑Year Growth and $39 Price Target
PremiumRatings
Ekterly: Strong Global Launch Momentum and Pediatric Upside Support Multi‑Year Growth and $39 Price Target
3M ago
KALV
KalVista announces interim Phase 3 data from KONFIDENT-KID trial of EKTERLY
PremiumThe Fly
KalVista announces interim Phase 3 data from KONFIDENT-KID trial of EKTERLY
3M ago
KALV
Sustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista
PremiumRatingsSustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista
3M ago
KALV
KalVista price target lowered to $28 from $29 at Citizens
Premium
The Fly
KalVista price target lowered to $28 from $29 at Citizens
3M ago
KALV
KalVista price target raised to $42 from $39 at Stifel
Premium
The Fly
KalVista price target raised to $42 from $39 at Stifel
3M ago
KALV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >